Pfizer, Moderna, and J&J pledge more shots for poorer countries

  • Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), and Johnson & Johnson (NYSE:JNJ) have pledged to provide additional COVID-19 vaccine jabs to poorer countries.
  • The announcement was made at a G20 meeting.
  • Pfizer has said it will supply 1B doses next year for low and middle-income countries, in addition to a similar amount for this year.
  • J&J is in discussions to supply 300M doses next year as Gavi, a global vaccines alliance, announced plans today to purchase 200M of the company's vaccines.
  • AstraZeneca (NASDAQ:AZN) previously agreed to provide vaccines at a cost to COVAX, an initiative to provide more equitable vaccine distribution.

    For this year the company, based in New York City revenue will be around 73.07 billion USD. This is according to the average of the analysts' estimates. This is quite more than 2020's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2020

    beurskoers

    The analysts expect for 2021 a net profit of 21.48 billion USD. The majority of the analysts expects for this year a profit per share of 3.76 USD. Based on this the price/earnings-ratio is 10.59.

    Huge dividend Pfizer

    Per share the analysts expect a dividend of 1.57 USD per share. The dividend yield is then 3.94 percent. The average dividend yield of the pharmaceutical companies equals a limited 1.39 percent.

    Latest estimates around 42 USD

    The latest 3 recommendations for the pharmaceutical company were provided by JP Morgan, Goldman Sachs and KBC Securities.

    Pfizer 's market value equals around 220.31 billion . The Pfizer stock was the past 12 months quite volatile. Since last May the stock is 17 percent higher. This year the stock price moved between 30 and 43 dollar.

    Historical stock prices Pfizer2007-2021

    stock price pfizer

    On Monday the stock closed at 39.81 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.